cyrilzakka/clinical-trials huggingface dataset:
Blood Flow Response and Acute INterval Exercise

The objective of this project is to study the cerebrovascular response to a single bout of high intensity interval exercise (HIIT) in 25 individuals with chronic stroke compared to 25 age- and sex- matched healthy controls (CON). We will enroll 25 young healthy adults (CONyoung) as a reference group. Our hypothesis is that the cerebrovascular response in individuals with chronic stroke will be significantly lower: 1) during a single bout of HIIT, and 2) during the recovery immediately following and 30 minutes after HIIT, compared to CON.

This study has 2 visits at the University of Kansas Medical Center Research in Exercise and Cardiovascular Health Laboratory. For the first visit, we will perform questionnaires about heart health, physical activity and overall health. Participants will then complete a submaximal exercise test on a seated stepper. Participants will also have a familiarization session to practice HIIT. The second visit will include cerebrovascular measures before, during, immediately after, and 30 minutes after performing HIIT.


Eligibility Criteria:
Chronic Stroke Inclusion Criteria:

* Age 40-80 years old
* Treated for stroke 6 months to 5 years ago
* Performs \<150 minutes of moderate intensity exercise per week
* Able to answer consenting questions and follow a 2-step command

Chronic Stroke Exclusion Criteria:

* Stroke etiology due to COVID-19 pathology.
* Symptoms of COVID-19 and/or Positive COVID-19 test within the past 3 months
* Unable to stand from a sitting position without physical assistance
* Recent joint replacement/surgery/poor motor control that limits ability to perform exercise on a recumbent stepper
* Insulin injection dependent diabetes
* Dependent on supplementary oxygen
* History of other neurological disease (Multiple Sclerosis, Alzheimer's disease, Parkinson's disease)
* Unable to find TCD signal on the stroke-affected or non-affected MCA.

CON Inclusion Criteria:

* Matched age ± 5 years to participant with chronic stroke
* Matched sex to participant with chronic stroke
* Performs \<150 minutes of moderate intensity exercise per week
* Able to answer consenting questions and follow a 2-step command

CON Exclusion Criteria:

* Symptoms of COVID-19 and/or Positive COVID-19 test within the past 3 months
* Unable to stand from a sitting position without physical assistance
* Recent joint replacement/surgery/poor motor control that limits ability to perform exercise on a recumbent stepper
* Insulin injection dependent diabetes
* Dependent on supplementary oxygen
* History of other neurological disease (Multiple Sclerosis, Alzheimer's disease, Parkinson's disease)
* Unable to find TCD signal on the right or left MCA.

CONyoung Inclusion Criteria:

* Age 18-30 years old
* Low cardiac risk (defined by the American College of Sports Medicine)
* Able to find TCD signal on the right or left MCA
Radiographic Evaluation in Alveolar Preservation Using Platelet-rich Fibrin. Randomized Controlled Trial

This randomized controlled trial is designed to assess the use of platelet-rich fibrin (PRF), a biomaterial derived from a participant's own blood, in alveolar ridge preservation following premolar extraction for orthodontic purposes. Participants aged 17 to 38 years requiring premolar extractions will be randomly assigned to receive either PRF application or natural healing without intervention. Cone beam computed tomography (CBCT) will be used to evaluate changes in alveolar bone dimensions and density at 30 and 120 days post-extraction. Measurements will be taken at standardized vertical levels (1 mm, 3 mm, and 5 mm apical to the crest) to analyze bone height, width, and density over time.

This study is a randomized controlled clinical trial designed to investigate the application of platelet-rich fibrin (PRF) in post-extraction sites following orthodontically indicated premolar removals. PRF is prepared from autologous blood and applied to extraction sockets in the experimental group, while the control group undergoes standard physiological healing. Cone beam computed tomography (CBCT) will be used to obtain quantitative data on alveolar bone structure at baseline, 30 days, and 120 days post-extraction. The study will assess changes in bone height, horizontal ridge width at defined depths, and bone tissue density using standardized imaging protocols. This design allows for objective comparison between treated and untreated sites.

Eligibility Criteria:
Inclusion Criteria:

* Healthy individuals with no systemic diseases.
* Age range: 17 to 38 years old.
* Orthodontic indication for premolar extraction (two maxillary or two mandibular premolars).
* Candidates for orthognathic surgery or extraction of impacted/retained teeth (e.g., third molars with a relationship to critical anatomical structures).
* Clinical justification for CBCT imaging instead of standard radiographic -techniques.

Exclusion Criteria:

* Patients with systemic diseases that may alter periodontal therapy outcomes.
* Platelet count below 200,000 mm³.
* Immunosuppressed patients.
* Pregnant or lactating women.
* Smokers.
* Patients taking medications that interfere with healing (e.g., bisphosphonates, corticosteroids, anticoagulants).
Role of Antioxidants (Vitamin C and E) in the Management of Schizophrenia

Background: Antioxidants are substances that are considered as a defensive material which protects cells from destruction. It is evident that use of food stuff rich in antioxidant will fortify one's ability to encounter with physical \& mental disorders. Since, among several potential elucidations, oxidative stress is more likely deliberated as one of the causative factors which give rise to cognitive and functional impairment. This deterioration further result in intricacy in ones thought process as progressive brain changes crop-up schizophrenic unfold. Therefore, this study was conducted with objectives to explore the role of selected antioxidants (vitamin C \& E) and to compare the role of both vitamins as an add-on management of schizophrenia .Materials \& Methods: One hundred and five patients were selected from department of psychiatry King Edward Medical University Lahore, and assigned into 3 groups by simple random lottery method. For eight weeks, Vitamin C group intervened with 500mg vitamin C tablet once a day, vitamin E group with 600IU vitamin E twice daily and placebo group was given 500 mg paraffin oil capsule daily. PANSS scale was used to assess the symptoms of schizophrenia. Demographic information was collected by structured questionnaire. Dietary habits were assessed by food frequency questionnaire.

Background: Antioxidants such as Vitamin C and E are substances that are considered as a defensive material which protects cells from destruction. It is evident that use of food stuff rich in antioxidant will fortify one's ability to encounter with physical \& mental disorders. Since, among several potential elucidations, oxidation stress is more likely deliberated as one of the causative factors which give rise to cognitive and functional impairment. Therefore, this study was conducted with objectives to explore the role of selected antioxidants (vitamin C \& E) and to compare the role of both vitamins as an add-on management of schizophrenia .Materials \& Methods: One hundred and five patients were selected from department of psychiatry King Edward Medical University Lahore, and assigned into 3 groups by simple random lottery method. For the period of two months, Vitamin C group intervened with 500 mg vitamin C tablet once a day, vitamin E group with 600 I U vitamin E twice daily and placebo group was given 500 mg paraffin oil capsule daily. PANSS (Positive and Negative Symptoms Scale) was used to assess the symptoms of schizophrenia. Demographic information was collected by structured questionnaire. Dietary habits were assessed by (FFQ) food frequency questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* INCLUSION CRITERIA:

  * All diagnosed schizophrenic patients 20-50 years of age
  * visited department of psychiatry \& behavioral sciences King Edward medical university Lahore.
* EXCLUSION CRITERIA:

  * Patients diagnosed with axis i and axis ii disorders
  * having any other pathological condition like hypertension, hyperlipidemia, and cardiac disorders.

Exclusion Criteria:

-
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Investigate the safety, tolerability and pharmacokinetics of BAY1093884 after Intravenous (IV) and subcutaneous (SC) administration of increasing single doses and SC administration of multiple doses.


Eligibility Criteria:
Inclusion Criteria:

* Males with severe congenital Hemophilia A or B defined as \<1% FVIII or Factor IX (FIX) concentration by measurement at the time of screening or from reliable prior documentation
* For subjects in Cohorts I-IV, I-SC1 and I-SC2; If history of inhibitors is evident, inhibitor titer of ≥5 Bethesda Units (BU) at screening or prior to screening at any time from medical records.
* Age: 18 to 65 years of age at screening
* Body mass index (BMI): 18 to 29.9 kg/m²

Exclusion Criteria:

* Subjects with known bleeding disorders (such as von Willebrand factor \[vWF\] deficiency, FXI deficiency, platelet disorders, or known acquired or inherited thrombophilia etc.) other than congenital Hemophilia A or B with or without inhibitors
* History of angina pectoris or treatment for angina pectoris
* History of coronary and/or peripheral atherosclerotic disease, congestive heart failure, disseminated intravascular coagulopathy, or stage 2 hypertension defined as systolic blood pressure (SBP) ≥160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg even if controlled
* History of thrombophlebitis, venous / arterial thromboembolic diseases (particularly deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, cerebrovascular accident, ischemic heart disease, transient ischemic attack)
* Known or suspected hypersensitivity of the immune system, history of anaphylactic reaction, known (clinically relevant) allergies, non-allergic drug reactions, or multiple drug allergies
Pioglitazone in Impaired Glucose Tolerance

In patients with impaired glucose tolerance (IGT), the researchers want to study the relative effects of pioglitazone, simvastatin, or the combination of both on:

* intima media thickness (IMT) as an easily assessed marker of atherosclerosis
* heart rate variability (HRV) as a marker of autonomic neuropathy
* flow-mediated vasodilatation (FMD) of the brachial artery as a marker of endothelial function
* vascular and metabolic lab parameters

We want to study the relative effects of pioglitazone, simvastatin or the combination of both on intima media thickness (IMT), heart rate variability (HRV), flow-mediated vasodilatation (FMD) of the brachial artery and vascular/metabolic lab parameters in patients with impaired glucose tolerance (IGT). Previous studies have shown a reduction in IMT for both pioglitazone and simvastatin in type 2 diabetics. Many patients with diabetes mellitus develop diabetic polyneuropathy which can be assessed by measuring HRV. It has been shown that pioglitazone has a positive effect on HRV in type 2 diabetics. Questions remain on the relative efficacy of pioglitazone and simvastatin on the parameters mentioned above. Also, there is only scarce data in patients with IGT (as opposed to overt diabetes mellitus). There are no data on the relative effects of pioglitazone and simvastatin on flow-mediated vasodilatation (FMD) of the brachial artery as a surrogate marker for endothelial function.

Eligibility Criteria:
Inclusion Criteria:

* Impaired glucose tolerance
* Age 40 to 75 years

Exclusion Criteria:

* Diabetes mellitus type 1 or 2
* Hypersensitivity to study medication
* Malignant tumor
* Alcohol or drug abuse
* Overt heart failure
* Severe hepatic, renal, neurological, psychiatric, or hematological disease
* Prior treatment with glitazones or statins
* Established indication for statin treatment (e.g. coronary artery disease \[CAD\])
Modulation of Cerebral Blood Flow Using Iron Chelators

The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.


Eligibility Criteria:
Inclusion Criteria:

* healthy adults between the ages of 18-80 years.

Exclusion Criteria:

* subjects taking vasoactive medications,
* hypertension,
* pregnant women, smokers,
* COPD,
* asthma,
* diabetes mellitus,
* intracranial or carotid stenosis,
* hepatic disease,
* renal disease,
* bone marrow suppression,
* cardiac disease,
* heart failure,
* iron deficiency,
* history of cancer,
* history of head trauma,
* subarachnoid hemorrhage,
* central nervous system vasculitis,
* multiple sclerosis,
* migraines,
* seizures,
* sickle cell disease or trait,
* cardiac arrhythmia,
* unable to give informed consent, or
* poor transcranial Doppler insonation windows.
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.

This study will investigate whether taking MitoQ for six months can improve the walking ability, daily activity levels, and quality of life of people with claudication (leg pain) caused by peripheral artery disease (PAD). We'll also look at how MitoQ affects their calf muscles.

Here's what we'll be checking:

Muscle health: We'll examine muscle tissue samples under a microscope to see if MitoQ improves muscle health and function.

Body chemistry: We'll check blood tests to see if MitoQ affects overall health markers.

Mitochondrial health: We'll see if MitoQ reduces damage to mitochondria (the cell's powerhouses) and helps the body get rid of damaged ones. We'll also see if it improves how well mitochondria function.

Blood flow: We'll measure blood flow in the legs and see if MitoQ improves the function of tiny blood vessels in the calf muscles.

In short, we want to see if MitoQ can improve various aspects of health in people with claudication and PAD, and if these improvements are linked to better functioning mitochondria in their muscles.

Eligibility Criteria:
Inclusion Criteria:

1. a positive history of chronic claudication
2. exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon
3. documented lower extremity arterial occlusive disease based on ankle/brachial index measurements and/or arterial imaging
4. stable blood pressure, lipid and diabetes regimens and risk factor control for 6 weeks.

Exclusion Criteria:

1. rest pain or tissue loss due to PAD (Fontaine stage III and IV)
2. acute lower extremity ischemic event
3. walking capacity significantly and primarily limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology.
Assessment of Early Genetic Changes in Smokers

This study will look at the genetic profile of cells taken from the oral cavity of healthy college students who smoke and who do not smoke cigarettes. This will be done using a small brush similar to that used in Pap tests for cervical cancer detection. Our aim is to determine if smoking causes early genetic changes in the DNA of these cells such as have been seen in the cells of cancerous tumors of the head and neck area and nearby healthy tissues. This will be correlated with data from subject questionnaires to assess tobacco use, and other behavior and demographic information.

Our pilot study using cellular DNA (cDNA) microarrays to examine the buccal mucosa of smokers and non-smokers demonstrated that smokers could be separated from non-smokers based solely on the patterns of gene expression observed. We were able to identify 924 genes whose expression differs significantly between samples from smokers and non-smokers. Several genes were also shown to be either up or down regulated in our earlier research applying microarray analysis to head and neck cancer tumors. Many of these represent genes of possible interest as early molecular markers for head and neck carcinogenesis.

Aberrant methylation is an important event in the transcriptional silencing of candidate tumor suppressor genes in smoking associated malignancies. Furthermore, it is known that methylated CpG islands are the preferred binding site for benzo(a)pyrene diol epoxide and other carcinogens found in tobacco smoke. Binding of these compounds is known to cause DNA adducts and transversion mutations that are often observed in the aerodigestive tumors of smokers. New evidence suggests that specific DNA methylation events are directly linked to tobacco use. The ability to detect such molecular markers during screening of high risk groups would represent a significant advance in cancer screening and early detection. Our group has evaluated specimens to epigenetically profile CpG island hypermethylation in. head and neck squamous cell carcinoma ( HNSCC) tumor samples using a technique known as methylation specific restriction enzyme microarray analysis. This method will be used in this trial to detect alterations in global DNA methylation patterns in subjects who smoke compared to those who don't.

The objectives of this study are:

1. Test the hypothesis that there are specific genetic alterations, leading to gene expression profile changes, which will be detected in early smokers.
2. Test the hypothesis that early smokers will demonstrate alterations in global DNA methylation patterns compared to matched controls.
3. To analyze gene alterations and DNA methylation in college smokers over time through longitudinal follow-up.

Eligibility Criteria:
Inclusion Criteria:

College freshmen and sophomores

Smokers must be between the ages of 18 and 25

Smokers must have smoked regularly for at least 2 years and be currently smoking

Smokers must intend to stay in the New York area for at least 3 years.

Non-smokers must be non-users of marijuana -

Exclusion Criteria:

Current HIV/AIDS infection

Use of chewing tobacco

-
Normal Range of Superior Mesenteric Artery in Young Chinese Population and Its Correlation With Retroperitoneal Adipose Tissue

In literature, superior mesenteric artery (SMA) angle, also named as aortomesenteric angle (AMA), varies greatly in both adult and children; while the aortomesenteric distance also ranges widely. Both AMA and AMD are influenced by retroperitoneal fat. Decrease of AMA and AMD may lead to the superior mesenteric artery syndrome(SMAS), which is a rare medical condition mainly presenting with duodenum obstruction. To our knowledge, normal range of AMA and AMD in local young Chinese population remain unclear; on the other hand, there have only a few studies exploring the relationship between them. This project proposes to establish the normal range of AMA and AMD in local young Chinese population, and to further investigate how the retroperitoneal adipose tissue correlates with AMA and AMD. The normal range obtained in this proposed study will provide more specific reference value to distinguish abnormal AMA and AMD, and to improve the diagnosis accuracy of SMAS in local population. Moreover, this study will provide deeper insight concerning the impact of retroperitoneal fat on AMA and AMD.


Eligibility Criteria:
Inclusion Criteria:

* With age range of 10-35 years old.
* Chinese ethnicity.
* With abdomen contrast CT.

Exclusion Criteria:

* Any patients with diagnosis of SMAS will be excluded from the Non-SMAS group.
* Patients who had undergone more than one CT scan during the research period.
* Previous retroperitoneal, abdominal surgery.
* Conditions causing significant weight loss, e.g. anorexia nervosa, malabsorption.
* Presence of abdominal masses or pathology that will affect the anatomy of aorta- superior mesenteric artery and the retroperitoneal structures.
* Presence of severe scoliosis and/or history of spinal fixation that may increase incidence of SMA syndrome.
* Presence of free intraperitoneal or retroperitoneal fluid that may affect fat measurement, e.g. following trauma, or ascites.
Safer Use of Medication in Pediatric Patients at Home

This study aims:

* to develop a web-based notification system for caregivers of pediatric patients that allows to report medication errors and, based on this notification, and to share experiences and alerts about common errors of patients.
* to assess de user satisfaction and perceived usefulness of the system.

Participants:

Parents with children who have required drug treatment in the last two months, who have an Internet connection and who agree to participate in the study.

Sample size: 62 participants

Main outcome variable: overall satisfaction


Eligibility Criteria:
Inclusion Criteria:

* To care children aged under 14 years who have required drug treatment in the last two months
* To have an Internet connection
* To agree to participate in the study.
* To be registered in the study web-based notification system
* Age \> 17 years

Exclusion Criteria:

* To be health provider
* To care children in residence for minors.
* To care children with a life expectancy of less than 2 years.
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental: rilzabrutinib with glucocorticoids and (2) Active Comparator: glucocorticoids only.

4 weeks of screening, 12 weeks of main treatment, 12 weeks of cross-over (for GC-only group), 40 weeks of extension treatment and 4-week follow-up.

Eligibility Criteria:
Key Inclusion Criteria:

* Be male or female with age ≥18 years.
* Have a clinical diagnosis of IgG4-RD.
* Be willing to taper off an equivalent prednisone dose of between 20-40 mg/day in 2 weeks.

Key Exclusion Criteria:

* Currently or within 6 months of screening taking rituximab, other B-cell depleting agents, or alkylating agents unless B cell concentrations have been demonstrated by flow cytometry to return to normal values (defined as 5 cells per cubic mm).
* History of solid organ transplant
* Positive at Screening for HIV, hepatitis B, hepatitis C, or TB
* Female patients who are pregnant or nursing.
* NOTE: Other Inclusion/Exclusion criteria may apply.